AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...

AstraZeneca’s fixed-dose triple-combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma: Cambridge, UK Saturday, May 3, 2025, 10:00 Hrs ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results from the Phase III KALOS and LOGOS trials in ...

Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca's Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumar ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

AstraZeneca said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for ...